Fiche centre
University of Pennsylvania
Philadelphia — United States
Essais liés54clinical trials
VillePhiladelphialocalisation
PaysUnited Stateslocalisation
SourcelocaleCSV/MySQL
Informations
centreSynchronisé depuis ClinicalTrials.gov — NCT07110454
Essais cliniques associés
54| Molécule | Indication / population | Phase | NCT | Titre | Statut |
|---|---|---|---|---|---|
| Lab Assay for seven genetic variants for Parkinson's Disease | Parkinson | À vérifier | NCT04994015 | Parkinson's Foundation PD GENEration Genetic Registry | RECRUITING |
| Pitolisant Oral Tablet | Myopathies | Phase 2 | NCT04886518 | Safety and Efficacy of Pitolisant on Excessive Daytime Sleepiness and Other Non-Muscular Symptoms in Patients With Myotonic Dystrophy Type 1 | COMPLETED |
| BBP-418 (ribitol) | Myopathies | Phase 3 | NCT05775848 | Fortify — Study to Evaluate the Efficacy and Safety of BBP-418 (Ribitol) in Patients With Limb Girdle Muscular Dystrophy 2I (LGMD2I) | ACTIVE_NOT_RECRUITING |
| lorundrostat | Hypertension | Phase 3 | NCT05968430 | Open-Label Extension (OLE) Study to Assess Safety, Efficacy, and Tolerability of Lorundrostat in Subjects With Hypertension | ACTIVE_NOT_RECRUITING |
| RO7046015 | Parkinson | Phase 2 | NCT03100149 | PASADENA — A Study to Evaluate the Efficacy of Prasinezumab (RO7046015/PRX002) in Participants With Early Parkinson's Disease | ACTIVE_NOT_RECRUITING |
| CAVS-MS — Central Vein Sign: a Diagnostic Biomarker in Multiple Sclerosis | SEP | À vérifier | NCT04495556 | CAVS-MS — Central Vein Sign: a Diagnostic Biomarker in Multiple Sclerosis | ACTIVE_NOT_RECRUITING |
| Ocrelizumab | SEP | Phase 1 | NCT03972306 | A Study To Investigate The Pharmacokinetics, Safety, And Tolerability Of Subcutaneous Ocrelizumab Administration In Participants With Multiple Sclerosis | COMPLETED |
| AOC 1001 (del-desiran) | Myopathies | Phase 3 | NCT06411288 | HARBOR — Global Study of Del-desiran for the Treatment of DM1 | COMPLETED |
| BRAIN — Biofluid Research on Age-Related or Inherited Neurodegeneration | Sclérose latérale amyotrophique | À vérifier | NCT07798700 | BRAIN — Biofluid Research on Age-Related or Inherited Neurodegeneration | RECRUITING |
| Nerandomilast | Myopathies | Phase 3 | NCT07789015 | VERANDA™-IIM — A Study to Understand How Nerandomilast Works in People With Active Idiopathic Inflammatory Myopathies | NOT_YET_RECRUITING |
| KYV-101 anti-CD19 CAR-T cell therapy | Lupus | Phase 1/2 | NCT05938725 | KYSA-1: A Study of Anti-CD19 Chimeric Antigen Receptor T-Cell (CD19 CAR T) Therapy, in Subjects With Refractory Lupus Nephritis | TERMINATED |
| Partial Nephrectomy (PN) | Cancer | À vérifier | NCT05363657 | i-RECORd — International REgistry of COnservative or Radical Treatment of Localized Kidney Tumors | RECRUITING |
| Ocrelizumab | SEP | À vérifier | NCT02807285 | Expanded Access Program for Ocrelizumab in Participants With Primary Progressive Multiple Sclerosis | NO_LONGER_AVAILABLE |
| Anakinra | Épilepsie | Phase 3 | NCT07281027 | COMparison Between Anakinra and Tocilizumab in NORSE - "COMBAT-NORSE" | NOT_YET_RECRUITING |
| BHV-7000 | Épilepsie | Phase 2/3 | NCT06132893 | RISE 2 — A Study to Determine if BHV-7000 is Effective and Safe in Adults With Refractory Focal Onset Epilepsy | RECRUITING |
| PGB2 — Phenotype, Genotype and Biomarkers 2 | Sclérose latérale amyotrophique | À vérifier | NCT04875416 | PGB2 — Phenotype, Genotype and Biomarkers 2 | ACTIVE_NOT_RECRUITING |
| Phenotype, Genotype & Biomarkers in ALS and Related Disorders | Sclérose latérale amyotrophique | À vérifier | NCT02327845 | Phenotype, Genotype & Biomarkers in ALS and Related Disorders | ACTIVE_NOT_RECRUITING |
| TRIAL READY (Clinical Trial Readiness) | Sclérose latérale amyotrophique | À vérifier | NCT03912987 | TRIAL READY (Clinical Trial Readiness) | ACTIVE_NOT_RECRUITING |
| VTx-002 | Sclérose latérale amyotrophique | Phase 1/2 | NCT07287397 | Study is to Assess the Safety and Tolerability of VTx-002 in Participants With ALS | RECRUITING |
| VX-670 | Myopathies | Phase 1/2 | NCT06185764 | Galileo — A Phase 1/2 Study of VX-670 in Adult Participants With Myotonic Dystrophy 1 (DM1) | ACTIVE_NOT_RECRUITING |
| Previous receipt of the Minder System (implantable continuous electroencephalographic (EEG) monitoring (iCEM) system) | Épilepsie | À vérifier | NCT07110454 | DETECT LTFU — Diagnosing Epilepsy To EffeCT Change Long-Term Follow-Up | RECRUITING |
| Receipt of the Minder System (implantable sub-scalp continuous electroencephalographic (EEG) monitoring (iCEM) system) | Épilepsie | Non applicable | NCT07110337 | DETECT — Diagnosing Epilepsy To EffeCT Change | RECRUITING |
| INO-5401 | Cancer | Phase 1 | NCT04367675 | INO 5401 Vaccination in BRCA1/2 Mutation Carriers | ACTIVE_NOT_RECRUITING |
| Neuraceq | Alzheimer | À vérifier | NCT05617014 | ADNI4 — Alzheimer's Disease Neuroimaging Initiative 4 | ENROLLING_BY_INVITATION |
| BBP-418 (ribitol) | Myopathies | Phase 3 | NCT07678775 | Open-Label Extension Study of BBP-418 (Ribitol) for LGMD2I/R9 | ACTIVE_NOT_RECRUITING |
| AOC 1020 | Myopathies | Phase 2 | NCT06547216 | FORTITUDE-OLE — Phase 2 Open-label Extension Study of AOC 1020 in Participants With Facioscapulohumeral Muscular Dystrophy (FSHD) | ACTIVE_NOT_RECRUITING |
| AOC 1020 | Myopathies | Phase 1/2 | NCT05747924 | FORTITUDE — Phase 1/2 Study of AOC 1020 in Participants With Facioscapulohumeral Muscular Dystrophy (FSHD) | COMPLETED |
| Adalimumab | Parkinson | Phase 2 | NCT06996652 | PRISMS — An Exploratory Study of the Potential for Rational Immune System Manipulation to Prevent Emergence of Synucleinopathy Manifestations in Persons With REM Sleep Behavior Disorder (RBD) | RECRUITING |
| ASSESS ALL ALS Study | Sclérose latérale amyotrophique | À vérifier | NCT06578195 | ASSESS ALL ALS Study | RECRUITING |
| ARTFL LEFFTDS Longitudinal Frontotemporal Lobar Degeneration (ALLFTD) | Sclérose latérale amyotrophique | À vérifier | NCT04363684 | ARTFL LEFFTDS Longitudinal Frontotemporal Lobar Degeneration (ALLFTD) | RECRUITING |
| RE104 for Injection | Sclérose latérale amyotrophique | Phase 2 | NCT07002034 | RE104 Safety and Efficacy Study in Adjustment Disorder in Cancer and Other Medical Illnesses | RECRUITING |
| Mechanical insufflation | Sclérose latérale amyotrophique | Non applicable | NCT06119087 | Mechanical Insufflation in the Philadelphia Amyotrophic Lateral Sclerosis Cohort (MI-PALS) Study | COMPLETED |
| Mycophenolate Mofetil | Myasthénie | À vérifier | NCT03490539 | PROMISE-MG — Disease-Modifying Treatments for Myasthenia Gravis | COMPLETED |
| Del-desiran (AOC 1001) | Myopathies | Phase 3 | NCT07008469 | HARBOR-OLE — Global Open-Label Extension Study of Del-desiran for the Treatment of DM1 | ENROLLING_BY_INVITATION |
| AOC-1020 | Myopathies | Phase 3 | NCT07038200 | FORTITUDE-3 — A Study to Evaluate Del-brax (Also Referred to as AOC 1020) in Participants With FSHD | RECRUITING |
| Sevasemten 10 mg | Myopathies | Phase 2 | NCT05291091 | Phase 2 Study of EDG-5506 in Becker Muscular Dystrophy (GRAND CANYON) | ACTIVE_NOT_RECRUITING |
| Sevasemten | Myopathies | Phase 2 | NCT06066580 | MESA — Open-Label Extension of EDG-5506 in Participants With Becker Muscular Dystrophy | ENROLLING_BY_INVITATION |
| delpacibart zotadirsen | Myopathies | À vérifier | NCT07250737 | Managed Access Program for Del-zota in Participants With DMD Mutations Amenable to Exon 44 Skipping | AVAILABLE |
| BIIB059 (litifilimab) | Lupus | Phase 3 | NCT06044337 | AMETHYST LTE — A Long-Term Extension Study to Learn More About the Safety of Litifilimab (BIIB059) Injections and Whether They Can Improve Symptoms of Adult Participants Who Have Active Cutaneous Lupus Erythematosus | ENROLLING_BY_INVITATION |
| Litifilimab | Lupus | Phase 2/3 | NCT05531565 | AMETHYST — A 2-Part Study to Learn Whether Litifilimab (BIIB059) Injections Can Improve Symptoms of Adult Participants Who Have Active Cutaneous Lupus Erythematosus | ACTIVE_NOT_RECRUITING |
| XEN1101 | Épilepsie | Phase 3 | NCT05667142 | X-ACKT — A Study to Evaluate XEN1101 as Adjunctive Therapy in Primary Generalized Tonic-Clonic Seizures | RECRUITING |
| XEN1101 | Épilepsie | Phase 3 | NCT05718817 | X-TOLE4 — An Open-label Study of XEN1101 in Epilepsy | ENROLLING_BY_INVITATION |
| CT1812 | Alzheimer | Phase 2 | NCT05531656 | A Study to Evaluate the Safety and Efficacy of CT1812 in Early Alzheimer's Disease | ACTIVE_NOT_RECRUITING |
| Anti-hypertensive therapy | Hypertension | Phase 4 | NCT02299414 | Chronic Hypertension and Pregnancy (CHAP) Project | COMPLETED |
| Celecoxib | Sclérose latérale amyotrophique | Phase 2 | NCT00355576 | Combination Therapy Selection Trial in Amyotrophic Lateral Sclerosis | COMPLETED |
| Atogepant 60 mg | Migraine | Phase 4 | NCT06972056 | Comparative Effectiveness of Migraine Preventive Medications: The APT Comparison Study | RECRUITING |
| The Paradise® Renal Denervation Ultrasound System | Hypertension | Non applicable | NCT02649426 | RADIANCE-HTN — A Study of the ReCor Medical Paradise System in Clinical Hypertension | ACTIVE_NOT_RECRUITING |
| ADNI-GO — Alzheimer's Disease Neuroimaging Initiative Grand Opportunity | Alzheimer | À vérifier | NCT01078636 | ADNI-GO — Alzheimer's Disease Neuroimaging Initiative Grand Opportunity | COMPLETED |
| Living With Frontotemporal Dementia | Alzheimer | À vérifier | NCT01738386 | Living With Frontotemporal Dementia | TERMINATED |
| Descartes-08 | Myasthénie | Phase 2 | NCT04146051 | Descartes-08 CAR-T Cells in Generalized Myasthenia Gravis (MG) | ACTIVE_NOT_RECRUITING |
| Simvastatin | SEP | Phase 1 | NCT02061397 | Safety of Simvastatin in LAM and TSC | COMPLETED |
| pregabalin | Épilepsie | Phase 3 | NCT01262677 | Once-A-Day Pregabalin For Partial Seizures | COMPLETED |
| Early Longitudinal Imaging in Parkinson's Progression Markers Initiative Using [¹⁸F] AV-133 and DaTscan™ | Parkinson | À vérifier | NCT04507139 | Early Longitudinal Imaging in Parkinson's Progression Markers Initiative Using [¹⁸F] AV-133 and DaTscan™ | ACTIVE_NOT_RECRUITING |
| Zilucoplan | Sclérose latérale amyotrophique | Phase 2/3 | NCT04297683 | HEALEY ALS Platform Trial - Master Protocol | ACTIVE_NOT_RECRUITING |